On 1984 Canadian endocrinologists tried to examine the effect of low-dose, short term CsA for patients, newly diagnosed with type one diabetes mellitus, for remission and restoration of the beta cell function, think of them, it will suppress the fierceness of the autoimmune attack against islets of Langerhans. This topic was addressed extensively from 1984 till 1999, and no scholars thought to knock the door again. Although the conclusions of most of the articles were vague and neutral, most of the clinicians, till now insist to put CsA in the dock. It was an arbitrary verdict. We conducted this first meta-analysis to put points on the letters and cut doubt in certainty, that low-dose, short term CsA has no effect on this kidney, and if so it is trivial and reversible.